By discovering a new mechanism that allows blood to enter the brain immediately after a stroke, researchers at UC Irvine and the Salk Institute have opened the door to new therapies that may limit or prevent stroke-induced brain damage.
Patients with arteriovenous malformations (abnormal connection between arteries and veins) in the brain that have not ruptured had a lower risk of stroke or death for up to 12 years if they received conservative management of the condition compared to an interventional treatment, according to a study in the April 23/30 issue of JAMA, a neurology theme issue.
April 15, 2014—Reverse Medical Corporation (Irvine, CA) announced that the US Food and Drug Administration approved an investigational device exemption for a clinical study of the company’s Barrel vascular reconstruction device (VRD). The company advised that it will soon finalize the infrastructure for the Barrel VRD clinical trial and begin patient enrollment within the next few months.
Individuals suffering from spinal fractures - caused by osteoporosis or weakened bones - now have another option to reduce pain, restore function and improve quality of life, according to a study of 300 patients treated with a new type of vertebral augmentation. Results of a randomized, controlled multicenter trial on a new implant treatment for vertebral compression fractures are being reported for the first time at the Society of Interventional Radiology s 39th Annual Scientific Meeting.
Results from a randomised controlled trial that used the KIVA System (Benvenue) suggest that the vertebral augmentation device offers a new treatment option for individuals with compression fractures.
InspireMD announced that it has successfully enrolled the first patient in the CARENET (Carotid embolic protection study using MicroNet) multicentre European clinical trial for the new CGuard carotid embolic protection system.
April 11, 2014—Covidien (Mansfield, MA) announced that it has notified customers of a voluntary recall to address an issue with certain lots of its Pipeline embolization device and Alligator retrieval device, in which the polytetrafluoroethylene (PTFE) coating applied to the delivery wire could delaminate and detach from the devices. Delamination of the PTFE coating could potentially lead to embolic occlusion in the cerebral vasculature, with the risk of stroke or death. The PTFE coating is used to reduce friction between devices and ease navigation through the vasculature.
Clinicians prescribed opioids for almost half of the teenagers they treated for headache when medications, such as aspirin, ibuprofen and naproxen, are recommended as first-line therapies, according to a study in the Journal of Adolescent Health.
Stryker has announced the global launch of the new Trevo XP ProVue Retriever. According to a company release, the Trevo XP ProVue Retriever expands the ProVue Retriever line with additional size and shape options for physicians. The Trevo ProVue Retrievers are the world’s first stent retrievers with full-length visibility and are built on Trevo technology which has delivered strong clinical results and positive patient outcomes for acute ischaemic stroke patients.
Reverse Medical Corporation has announced the initial clinical use of their UNO neurovascular embolisation system for intracranial use. The device has been granted European Union CE mark approval to obstruct blood flow in the neurovasculature.
Codman Neuro announced that the US Food and Drug Administration (FDA) has classified the recently initiated medical device correction notice related to the Trufill n-BCA liquid embolic system as a Class I recall.
New stroke therapy, using a combination of non-invasive navigated transcranial stimulation along with occupational therapy, has been found to produce significant gains in motor function post-stroke, with an average of 50% of stroke survivors recovering full use of their arm.
Ornim Medical has announced that new study results demonstrate the feasibility of the Cerox cerebral oxidation monitor for measuring regional cerebral tissue oxygenation in patients with severe traumatic brain injury.
InspireMD has announced that its new CGuard carotid embolic protection system has been successfully implanted in recent procedures, including a patient treated during the 17th Annual Symposium on Interventional Cardiology & Angiology held in Hamburg, Germany on February 1, 2014.
Nevro Corp has announced that the 24-month results of a prospective European clinical study using Nevro’s Senza system delivering HF10 therapy were published in the journal Pain Medicine. The study was conducted in the UK and Belgium with 65 of the 72 implanted patients (90%) being available for data collection at two years.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos